Søren Thinggaard Hansen, a 17 year-plus veteran of pension fund Industriens Pension, has joined Novo to launch a private equity program.

Sompo contributed to a $13.5m round for Binah.ai, developer of a mobile app that uses video to assess a user's physical health.

Takeda's R&D park is accepting membership applications for Japan VC Consortium, a life sciences-focused venture capital and corporate venturing engagement centre.

OHSU's CNS disorder drug developer has launched with $76m from investors co-led by Arch Venture Partners and Cowen Healthcare Investments.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Johnson & Johnson Innovation – JJDC returned for Cue Health’s $100m series C round as the medical diagnostics system developer seeks regulatory approval for its Covid-19 test.

The cancer immunotherapy developer's latest round included pharmaceutical producers and co-founders Juno Therapeutics and WuXi AppTec.

The CNS disorder drug developer has launched with $76m from investors including Biogen, Bristol Myers Squibb and Pfizer Ventures.

GV co-led a series C round for the healthcare collaboration service together with F-Prime Capital, Andreessen Horowitz and Transformation Capital, taking its overall funding past $101m.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.